Long-term clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease: a single-centre prospective cohort study with baseline liver biopsy
Authors:
- 26 May 2023
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 17 (4) , 870-881
Abstract
Background There are limited data on the long-term adverse clinical outcomes of adults with metabolic dysfunction-associated fatty liver disease (MAFLD). Methods This is a single-centre prospective study of a well-characterized cohort of MAFLD patients who underwent liver biopsy and followed every 6–12 months for adverse clinical outcomes. Results The data for 202 patients were analyzed [median age 55.0 (48.0–61.3) years old; male, 47.5%; obese, 88.6%; diabetes mellitus, 71.3%; steatohepatitis, 76.7%; advanced fibrosis, 27.2%]. The median follow-up interval was 7 (4–8) years. The cumulative incidence of liver-related events, cardiovascular events, malignancy and mortality was 0.43, 2.03, 0.60 and 0.60 per 100 person-years of follow-up, respectively. Liver-related events were only seen in patient with advanced fibrosis at 9.1% vs 0% in patient without advanced liver fibrosis (p < 0.001). The cumulative incidence of liver-related events among patients with advanced fibrosis was 1.67 per 100 person-years of follow-up. When further stratified to bridging fibrosis and cirrhosis, the cumulative incidence of liver-related events was 1.47 and 3.85 per 100 person-years of follow-up, respectively. Advanced fibrosis was not significantly associated with cardiovascular events, malignancy or mortality. The cumulative incidence of liver-related events, cardiovascular events, malignancy and mortality were not significantly different between patients with and without steatohepatitis and between obese and non-obese patients. However, liver-related events were only seen among obese patients. Conclusion Overall, the cumulative incidence of liver-related event is low in patients with MAFLD, but it is much higher among those with advanced fibrosis. However, there is a relatively high cumulative incidence of cardiovascular event among patients with MAFLD.Keywords
Funding Information
- Universiti Malaya (RG536-13HTM, BKS067-2017)
This publication has 45 references indexed in Scilit:
- Noninvasive fatty liver markers predict liver disease mortality in the U.S. populationHepatology, 2015
- Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2015
- Liver cancer in Malaysia: Epidemiology and clinical presentation in a multiracial Asian populationJournal of Digestive Diseases, 2015
- Nonalcoholic Steatohepatitis Is the Second Leading Etiology of Liver Disease Among Adults Awaiting Liver Transplantation in the United StatesGastroenterology, 2015
- A novel 2-step approach combining the NAFLD fibrosis score and liver stiffness measurement for predicting advanced fibrosisHepatology International, 2014
- Fibrosis stage is the strongest predictor for disease‐specific mortality in NAFLD after up to 33 years of follow‐upHepatology, 2014
- Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S.Hepatology, 2013
- Prevalence and risk factors of non-alcoholic fatty liver disease in a multiracial suburban Asian population in MalaysiaHepatology International, 2012
- The metabolic syndrome—a new worldwide definitionThe Lancet, 2005
- Design and validation of a histological scoring system for nonalcoholic fatty liver disease†Hepatology, 2005